Trial Information

Summary: Do you have relapsing-remitting or secondary-progressive multiple sclerosis?

You may be eligible to participate in a study of RTL1000, a new drug that is thought to have a highly targeted action. Some therapies currently available to MS patients target the body’s natural defense system and may make patients vulnerable to infections or other illnesses. In contrast, the action of RTL1000 is thought to be aimed directly at the actions of immune system cells that cause damage to the nerve cell insulation. It is hoped that RTL1000 might allow control of MS symptoms without damaging the rest of the body’s natural immune defenses.

Objectives of the study are to evaluate the safety profile of a single dose of RTL1000 administered by intravenous infusion, to evaluate the pharmacokinetic profile of RTL1000 in a subset of subjects, and to evaluate the feasibility of assessing immunologic parameters in a subset of subjects. There is likely no benefit to individual subjects.

To be eligible for this study, you must be:

• Already diagnosed with either relapsing-remitting or secondary progressive MS.
• Between 18 and 65 years old.
• Not currently taking an anti-MS drug (for example, Avonex, Betaseron, Copaxone,
• Novantrone, or Tysabri). You may be on medication, such as prednisone or steroids, to control symptoms.
• Able to walk with a cane or crutches at least 66 feet without resting (EDSS score 0 to 6.5).

For more information, see http://www.clinicaltrials.gov/ct/show/NCT00411723 or contact the center nearest you. Assistance with travel expenses may be available.

If you would like to learn more about participating in this study, please send an e-mail message using the form below.